Squarepoint’s Impax Laboratories, Inc. IPXL Stock Holding History

Squarepoint’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-89,767	Closed	-$1.82M	–	2481
2017 Q3	$1.82M	Buy	+89,767	New	+$1.72M	0.04%	531
2017 Q1	–	Sell	-110,996	Closed	-$1.47M	–	2144
2016 Q4	$1.47M	Buy	110,996 +54,793	+97%	+$937K	0.06%	371
2016 Q3	$1.33M	Sell	56,203 -8,912	-14%	-$240K	0.09%	275
2016 Q2	$1.88M	Buy	+65,115	New	+$2.12M	0.12%	209

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Squarepoint's IPXL Position: Q4 2017 in Review

Squarepoint sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 89,767 shares — an estimated $1.82M sold.

Squarepoint first reported a position in IPXL in Q2 2016 and held it in 4 quarters. The position peaked at $1.88M in Q2 2016. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

Squarepoint reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
Squarepoint sold 89,767 Impax Laboratories, Inc. shares in Q4 2017, an estimated $1.82M.
Squarepoint first reported a position in Impax Laboratories, Inc. in Q2 2016 and held it in 4 quarters.
Squarepoint's Impax Laboratories, Inc. position peaked at $1.88M in Q2 2016.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Squarepoint's 13F filing for Q4 2017, filed 14 Feb 2018.